A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely ...

In data presented at the 128th annual meeting of the American Academy of Ophthalmology in Chicago, the two-year study finds ...

Here’s what to know about the irreversible eye disease at the center of the new National Geographic documentary Blink.

Up to half of patients showed significant improvement in study results presented at the American Academy of Ophthalmology ...

An international team of researchers has identified new drug targets for therapies that could benefit patients with different forms of retinitis pigmentosa and other inherited retinal diseases.

Researchers have identified new drug targets for therapies that could benefit patients with different forms of retinitis ...

Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading ophthalmic gene therapy company with ...

Retinitis pigmentosa is a leading cause of blindness in adults. This CEO leads a Dallas company aiming to develop the first ...

The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs ...